VETOQUINOL SA (VETO.PA) Stock Price & Overview

EPA:VETO • FR0004186856

79.9 EUR
+0.3 (+0.38%)
Last: Mar 10, 2026, 09:38 AM

The current stock price of VETO.PA is 79.9 EUR. Today VETO.PA is up by 0.38%. In the past month the price decreased by -7.98%. In the past year, price increased by 11.17%.

VETO.PA Key Statistics

52-Week Range68.7 - 91.5
Current VETO.PA stock price positioned within its 52-week range.
1-Month Range75 - 91.5
Current VETO.PA stock price positioned within its 1-month range.
Market Cap
949.212M
P/E
15.85
Fwd P/E
15.40
EPS (TTM)
5.04
Dividend Yield
1.03%

VETO.PA Stock Performance

Today
+0.38%
1 Week
-5.13%
1 Month
-7.98%
3 Months
+3.38%
Longer-term
6 Months -1.97%
1 Year +11.17%
2 Years -20.00%
3 Years -10.06%
5 Years -19.27%
10 Years +118.74%

VETO.PA Stock Chart

VETOQUINOL SA / VETO Daily stock chart

VETO.PA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to VETO.PA. When comparing the yearly performance of all stocks, VETO.PA turns out to be only a medium performer in the overall market: it outperformed 62.33% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
VETO.PA Full Technical Analysis Report

VETO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to VETO.PA. VETO.PA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VETO.PA Full Fundamental Analysis Report

VETO.PA Earnings

Next Earnings DateMar 18, 2026
Last Earnings DateOct 28, 2025
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
VETO.PA Earnings History

VETO.PA Forecast & Estimates

11 analysts have analysed VETO.PA and the average price target is 92.41 EUR. This implies a price increase of 15.66% is expected in the next year compared to the current price of 79.9.


Analysts
Analysts80
Price Target92.41 (15.66%)
EPS Next Y0%
Revenue Next Year-1.84%
VETO.PA Forecast & Estimates

VETO.PA Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

VETO.PA Financial Highlights

Over the last trailing twelve months VETO.PA reported a non-GAAP Earnings per Share(EPS) of 5.04. The EPS increased by 26.53% compared to the year before.


Income Statements
Revenue(TTM)532.39M
Net Income(TTM)60.08M
Industry RankSector Rank
PM (TTM) 11.28%
ROA 8.28%
ROE 10.59%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%5.9%
Sales Q2Q%-2.57%
EPS 1Y (TTM)26.53%
Revenue 1Y (TTM)-0.95%
VETO.PA financials

VETO.PA Ownership

Ownership
Inst Owners12.36%
Shares11.88M
Float3.81M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
VETO.PA Ownership

VETO.PA Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
1SAN SANOFI8.96183.392B
SAN SANOFI9183.103B
SNW SANOFI8.94183.103B
UCB UCB SA25.4249.872B
UNC UCB SA24.2348.472B
1MRK MERCK KGAA12.5346.826B
MRK MERCK KGAA13.3146.804B
BAYN BAYER AG-REG8.2536.929B
1BAYN BAYER AG-REG8.0336.914B
IPN IPSEN13.1612.923B
REC RECORDATI INDUSTRIA CHIMICA16.59.825B
TUB FINANCIERE DE TUBIZE N/A9.703B
VIRP VIRBAC SA16.142.886B

About VETO.PA

Company Profile

VETO logo image Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

Company Info

IPO: 2006-11-16

VETOQUINOL SA

Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex

Lure BOURGOGNE-FRANCHE-COMTE FR

Employees: 2519

VETO Company Website

VETO Investor Relations

Phone: 33384625555

VETOQUINOL SA / VETO.PA FAQ

What does VETO do?

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.


What is the current price of VETO stock?

The current stock price of VETO.PA is 79.9 EUR. The price increased by 0.38% in the last trading session.


Does VETOQUINOL SA pay dividends?

VETOQUINOL SA (VETO.PA) has a dividend yield of 1.03%. The yearly dividend amount is currently 0.85.


What is the ChartMill technical and fundamental rating of VETO stock?

VETO.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is VETOQUINOL SA (VETO.PA) stock traded?

VETO.PA stock is listed on the Euronext Paris exchange.


Can you provide the market cap for VETOQUINOL SA?

VETOQUINOL SA (VETO.PA) has a market capitalization of 949.21M EUR. This makes VETO.PA a Small Cap stock.


When does VETOQUINOL SA (VETO.PA) report earnings?

VETOQUINOL SA (VETO.PA) will report earnings on 2026-03-18, after the market close.